Seagen Announces Multiple ADCETRIS® (Brentuximab Vedotin) Presentations at the Upcoming ASH Annual Meeting

Rhea-AI Summary

Seagen Inc. (Nasdaq:SGEN) will showcase multiple presentations of ADCETRIS^® (brentuximab vedotin) at the upcoming 62^nd American Society of Hematology (ASH) Annual Meeting, occurring virtually from December 5-8, 2020. Notably, five-year data updates from the phase 3 ECHELON-1 and ECHELON-2 trials will be presented, demonstrating significant improvements in clinical outcomes when ADCETRIS is combined with chemotherapy in treating advanced-stage Hodgkin lymphoma and peripheral T-cell lymphoma. This meeting features 18 presentations highlighting ADCETRIS's role in ongoing and future cancer treatment strategies.

Positive

• Five-year results from ECHELON-1 and ECHELON-2 trials show improved clinical outcomes for patients treated with ADCETRIS plus chemotherapy.
• A total of 18 presentations at the ASH meeting will emphasize the continued efficacy and potential of ADCETRIS in various lymphoma treatments.

Negative

• None.

BOTHELL, Wash.--(BUSINESS WIRE)--Seagen Inc. (Nasdaq:SGEN) today announced multiple ADCETRIS^® (brentuximab vedotin) data presentations at the upcoming 62^nd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place virtually December 5-8, 2020. Data presentations will include five-year updates from the phase 3 ECHELON-1 and ECHELON-2 clinical trials evaluating ADCETRIS plus a chemotherapy combination regimen in frontline advanced stage Hodgkin lymphoma (HL) or frontline peripheral T-cell lymphoma (PTCL). ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical HL and expressed on the surface of several types of PTCL. ADCETRIS is being evaluated globally in more than 70 corporate- and investigator-sponsored clinical trials across multiple settings in lymphoma and other indications.

“At this year’s ASH meeting, ADCETRIS will be featured in 18 data presentations, including five-year analyses from the ECHELON-1 and ECHELON-2 phase 3 frontline trials,” said Roger Dansey, M.D., Chief Medical Officer at Seagen. “Reaching five-years without disease recurrence represents a significant clinical milestone for patients, as they may be considered disease-free at this time point. The five-year data presentations from our phase 3 ECHELON-1 and ECHELON-2 trials demonstrate ADCETRIS plus chemotherapy resulted in superior clinical activity and durable benefit when compared to outcomes with a standard chemotherapy regimen. We will also present additional analyses from trials evaluating ADCETRIS in combination with other therapies, with the goal of identifying potential new treatment strategies that improve outcomes for patients.”

Details of Seagen Presentations at ASH:

Abstract Title	Abstract #	Presentation Type / Date	Presenter
Company-Sponsored Trials
Frontline Brentuximab Vedotin as Monotherapy or in Combination for Older Hodgkin Lymphoma Patients	#471	Oral presentation / Sunday, Dec. 6 at 2:15 p.m. PT	C. Yasenchak
Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin lymphoma: 5-year Update of the ECHELON-1 Study	#2973	Poster presentation / Monday, Dec. 7, 7:00 a.m. - 3:30 p.m. PT	D. Straus
The ECHELON-2 Trial: 5-Year Results of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Versus CHOP in Frontline Treatment of Patients with CD30-positive Peripheral T-cell Lymphoma	#1150	Poster presentation / Saturday, Dec. 5, 7:00 a.m. - 3:30 p.m. PT	S. Horwitz
Economic Assessment of Diagnostic Revision in Peripheral T-cell Lymphoma	#1606	Poster presentation / Saturday, Dec. 5, 7:00 a.m. - 3:30 p.m. PT	N. Liu
Nivolumab Combined with Brentuximab Vedotin for Relapsed/Refractory Mediastinal Gray Zone Lymphoma: Primary Efficacy and Safety Analysis of the Phase 2 CheckMate 436 Study	#2045	Poster presentation / Sunday, Dec. 6, 7:00 a.m. - 3:30 p.m. PT	A. Santoro
Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching	#2499	Poster presentation / Sunday, Dec. 6, 7:00 a.m. - 3:30 p.m. PT	T. Phillips
Real-World Adherence to National Comprehensive Cancer Network (NCCN) Guidelines Regarding the Usage of PET/CT and Reported Deauville Scores in Advanced Stage Classical Hodgkin Lymphoma: A Community Oncology Practice Perspective	#2033	Poster presentation / Sunday, Dec. 6, 7:00 a.m. - 3:30 p.m. PT	C. Yasenchak
SGN-CD30C, an Investigational CD30-Directed Camptothecin Antibody-Drug Conjugate (ADC), Shows Strong Anti Tumor Activity and Superior Tolerability in Preclinical Studies	#2089	Poster presentation / Sunday, Dec. 6, 7:00 a.m. - 3:30 p.m. PT	M. Ryan
Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching	#3418	Poster presentation / Monday, Dec. 7, 7:00 a.m. - 3:30 p.m. PT	J. Burke
Nodal Peripheral T-Cell Lymphoma with T Follicular-Helper Phenotype: A Different Entity? Results of the Spanish Retrospective Real-T Study	#2972	Poster presentation / Monday, Dec. 7, 7:00 a.m. - 3:30 p.m. PT	AM. Garcia-Sancho
Results from the International, Multi-Center, Retrospective B-Holistic Study: Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma	#2979	Poster presentation / Monday, Dec. 7, 7:00 a.m. - 3:30 p.m. PT	B. Ferhanoglu
Investigator-Sponsored Trials
Increased Tumor Specific Cytotoxic T Cell Responses and Reversion to a Favorable Cytokine Profile after Treatment in Patients with Newly Diagnosed High Risk Hodgkin Lymphoma Treated on Children’s Oncology Group Trial- AHOD1331	#595	Oral presentation / Monday, Dec. 7 at 9:15 a.m. PT	H. Dave
Addition of Brentuximab Vedotin to Gemcitabine in Relapsed or Refractory T-Cell Lymphoma: Results of a LYSA Multicenter, Phase II Study. “The TOTAL Trial”	#1161	Poster presentation / Saturday, Dec. 5, 7:00 a.m. - 3:30 p.m. PT	O. Tournilhac
A Pilot Study of Brentuximab Vedotin, Rituximab and Dose Attenuated CHP in Patients 75 Years and Older with Diffuse Large B-Cell Lymphoma	#2102	Poster presentation / Sunday, Dec. 6, 7:00 a.m. - 3:30 p.m. PT	P. Reagan
Dose-Dense Brentuximab Vedotin Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Is Highly Active for Second Line Treatment in Relapsed/Refractory Classical Hodgkin Lymphoma: Final Results of a Phase I/II Study	#2964	Poster presentation / Monday, Dec. 7, 7:00 a.m. - 3:30 p.m. PT	R. Lynch
A Phase I Trial Assessing the Feasibility of Romidepsin Combined with Brentuximab Vedotin for Patients Requiring Systemic Therapy for Cutaneous T-Cell Lymphoma	#2970	Poster presentation / Monday, Dec. 7, 7:00 a.m. - 3:30 p.m. PT	S. Barta
Trials-in-Progress
Trial-in-Progress: Brentuximab Vedotin in Combination with Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)	#2112	Poster presentation / Sunday, Dec. 6, 7:00 a.m. - 3:30 p.m. PT	N. Bartlett
A Phase 1 Study of Sea-CD70 in Myeloid Malignancies	#2874	Poster presentation / Monday, Dec. 7, 7:00 a.m. - 3:30 p.m. PT	A. Aribi
Trial-in-Progress: Frontline Brentuximab Vedotin and CHP (A+CHP) in Patients with Peripheral T-Cell Lymphoma with Less Than 10% CD30 Expression	#2976	Poster presentation / Monday, Dec. 7, 7:00 a.m. - 3:30 p.m. PT	D. Jagadeesh

About Seagen

Seagen is a global biotechnology company that discovers, develops and commercializes transformative cancer medicines to make a meaningful difference in people’s lives. Seagen is headquartered in the Seattle, Washington area, and has locations in California, Canada, Switzerland and the European Union. For more information on the company’s marketed products and robust pipeline, visit www.seagen.com and follow @SeagenGlobal on Twitter.

Forward Looking Statements

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the therapeutic potential of ADCETRIS plus chemotherapy combination regimens in frontline advanced stage Hodgkin lymphoma (HL) and frontline peripheral T-cell lymphoma (PTCL), and in other indications. Actual results or developments may differ materially from those projected or implied in these forward-looking statements due to factors such as unexpected adverse events, adverse regulatory actions, the degree of utilization and adoption of an approved treatment regimen by prescribing physicians, the difficulty and uncertainty of pharmaceutical product development, negative or disappointing clinical trial results and risks related to the duration and severity of the COVID-19 pandemic. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the difficulty and uncertainty of pharmaceutical product development, the risk of adverse events or safety signals, the inability to show sufficient activity in clinical trials and the possibility of adverse regulatory actions. More information about the risks and uncertainties faced by Seagen is contained under the caption “Risk Factors” included in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020 filed with the Securities and Exchange Commission. Seagen disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.